Clinical Trial Detail

NCT ID NCT02960230
Title H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

brain stem glioma

malignant glioma

spinal cord glioma

Therapies

H3.3K27M peptide vaccine + Montanide ISA 51 + Nivolumab + Poly ICLC + Tetanus Toxoid peptide

H3.3K27M peptide vaccine + Montanide ISA 51 + Poly ICLC + Tetanus Toxoid peptide

Age Groups: adult child

No variant requirements are available.